The current clinical data suggests that VEN, as a highly specific therapeutic agent, hits the bulk of CLL cells, which rapidly induces cell death by direct inhibition of BCL-2 because most CLL cells highly express BCL-2 and are reliant on BCL-2 [2, 3]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.